NCT06908304Phase 3Recruiting

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Study sponsor: Maia Biotechnology

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-07-31Estimated
Enrollment · participants300Estimated
Source updated2026-01-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Primary completion date changed

Before: 29 Jul 2026. After: 31 Jul 2027.

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source